Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-413 in Relapsed or Refractory B-cell NHL
NCT05233033Phase 1Completed
- Sponsor
- Kymera Therapeutics
- Start
- Jun 2022
- Primary completion
- Jul 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment), Molecular Glues
- Countries
- 2
01
Overview
Phase 1, open-label trial of KT-413 in diffuse large B-cell lymphoma (DLBCL), Waldenström macroglobulinemia (WM), primary central nervous system lymphoma (PCNSL) and 1 more (3 arms), sponsored by Kymera Therapeutics. Primary endpoints: Maximum Tolerated Dose at 3 weeks, Dose Limiting Toxicities at 3 weeks and 2 more. Started Jun 2022; status: completed.
02
Drugs
KT-413
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Waldenström macroglobulinemia (WM)primary central nervous system lymphoma (PCNSL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05233033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233033.